.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090675

« Back to Dashboard
NDA 090675 describes IRINOTECAN HYDROCHLORIDE, which is a drug marketed by Teva Pharms Usa, Sun Pharma Global, Hospira, Hisun Pharm Hangzhou, Cipla Ltd, Pliva Lachema, Akorn, Hikma Farmaceutica, Sandoz Inc, Dr Reddys Labs Ltd, Eurohlth Intl Sarl, Accord Hlthcare, Emcure Pharms Ltd, Jiangsu Hengrui Med, Fresenius Kabi Usa, Qilu Pharm Co Ltd, Fresenius Kabi Oncol, Actavis Totowa, Mustafa Nevzat Ilac, and Sandoz, and is included in twenty-one NDAs. It is available from thirteen suppliers. Additional details are available on the IRINOTECAN HYDROCHLORIDE profile page.

The generic ingredient in IRINOTECAN HYDROCHLORIDE is irinotecan hydrochloride. There are thirty-two drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the irinotecan hydrochloride profile page.

Summary for NDA: 090675

Tradename:
IRINOTECAN HYDROCHLORIDE
Applicant:
Jiangsu Hengrui Med
Ingredient:
irinotecan hydrochloride
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 090675

Mechanism of ActionTopoisomerase Inhibitors

Suppliers and Packaging for NDA: 090675

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride
INJECTABLE;INJECTION 090675 ANDA Sagent Pharmaceuticals 25021-230 25021-230-02 1 VIAL in 1 CARTON (25021-230-02) > 2 mL in 1 VIAL
IRINOTECAN HYDROCHLORIDE
irinotecan hydrochloride
INJECTABLE;INJECTION 090675 ANDA Sagent Pharmaceuticals 25021-230 25021-230-05 1 VIAL in 1 CARTON (25021-230-05) > 5 mL in 1 VIAL

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength100MG/5ML (20MG/ML)
Approval Date:Dec 16, 2011TE:APRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength40MG/2ML (20MG/ML)
Approval Date:Dec 16, 2011TE:APRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc